Literature DB >> 12010239

18F-fluoro-2-deoxyglucose-positron emission tomography in the evaluation of nonseminomatous germ cell tumours at relapse.

D Sanchez1, J J Zudaire, J M Fernandez, J Lopez, J Arocena, G Sanz, M Gimenez, D Rosell, J E Robles, J M Berian.   

Abstract

OBJECTIVES: To compare the performance of 18F-fluoro-2-deoxyglucose-positron emission tomography (FDG-PET) and computed tomography (CT) in the follow-up of nonseminomatous germ cell tumours (NSGCT) in the retroperitoneum. PATIENTS AND METHODS: FDG-PET was used 25 times in 15 patients diagnosed with NSGCT. At the time of diagnosis five patients each were in stage I, II and III. Five patients had pure embryonal carcinoma, two had yolk sac tumours, one choriocarcinoma and seven had mixed tumours.
RESULTS: Eleven patients either presented with retroperitoneal disease or this did not disappear after chemotherapy. The results of both examinations coincided in 18 cases and were contradictory in the other seven, the difference being statistically significant (P=0.042).
CONCLUSION: In these patients FDG-PET detected the retroperitoneal relapse of NSGCT, in advanced stages treated with surgery plus chemotherapy, earlier than did CT; it also detected the presence of mature teratoma in residual retroperitoneal masses more accurately than CT. More extensive trials are needed before making conclusions about FDG-PET imaging as a routine method for NSGCT.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12010239     DOI: 10.1046/j.1464-410x.2002.02779.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  7 in total

1.  Primary hepatic choriocarcinoma in a 49-year-old man: report of a case.

Authors:  Ryosuke Sekine; Masanobu Hyodo; Masayuki Kojima; Yoshiyuki Meguro; Akifumi Suzuki; Taku Yokoyama; Alan T Lefor; Norio Hirota
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

Review 2.  [Value of imaging for lymph node metastases from renal cell, bladder, prostate, penile, and testicular cancers].

Authors:  J Stattaus; A Bockisch; M Forsting; S P Müller
Journal:  Urologe A       Date:  2005-06       Impact factor: 0.639

Review 3.  [Positron emission tomography (PET) for diagnosis and monitoring of treatment for urological tumors].

Authors:  S Machtens; A R Boerner; M Hofmann; W H Knapp; U Jonas
Journal:  Urologe A       Date:  2004-11       Impact factor: 0.639

4.  αvβ3 imaging can accurately distinguish between mature teratoma and necrosis in 18F-FDG-negative residual masses after treatment of non-seminomatous testicular cancer: a preclinical study.

Authors:  Nicolas Aide; Mélanie Briand; Pierre Bohn; Soizic Dutoit; Charline Lasnon; Jacques Chasle; Jean Rouvet; Romain Modzelewski; Antony Vela; Edwiges Deslandes; Pierre Vera; Laurent Poulain; Franck Carreiras
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-09-30       Impact factor: 9.236

5.  Bone marrow metastasis in a patient with non-seminomatous testicular germ cell tumor.

Authors:  Takashi Ueda; Ippei Takada; Teruki Shimizu; Saya Ito; Atsuko Fujihara; Takumi Shiraishi; Terukazu Nakamura; Osamu Ukimura
Journal:  IJU Case Rep       Date:  2022-04-10

Review 6.  Positron emission tomography (PET) in the urooncological evaluation of the small pelvis.

Authors:  S Machtens; J Serth; A Meyer; C Kleinhorst; K-J Ommer; U Herbst; M Kieruij; A R Boerner
Journal:  World J Urol       Date:  2007-07-12       Impact factor: 4.226

Review 7.  The role of positron emission tomography in germ cell cancer.

Authors:  Maria De Santis; Jörg Pont
Journal:  World J Urol       Date:  2004-03-16       Impact factor: 4.226

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.